【摘要】：目的比較替吉奧(S-1)與氟尿嘧啶(5-FU)在中國晚期胃癌患者中的有效性及安全性。方法檢索中國知網(wǎng)、萬方數(shù)據(jù)及PubMed,查找在中國晚期胃癌患者中應(yīng)用S-1與5-FU的多中心隨機(jī)對(duì)照試驗(yàn)(mcRCTs),采用RevMan 5.2軟件進(jìn)行Meta分析。結(jié)果納入4個(gè)mcRCTs。Meta分析顯示S-1可以顯著提高客觀緩解率[OR=1.90,95%CI(1.36~2.65),P0.01]和疾病控制率[OR=2.08(1.43~3.03),P0.01],但未顯示出總生存優(yōu)勢(shì)[HR=0.76(0.39~1.50),P=0.82]。S-1組的白細(xì)胞減少[1~4級(jí):OR=2.40(1.41~4.07),P0.01;3~4級(jí):OR=3.09(1.94~4.93),P0.01]、中性粒細(xì)胞減少[1~4級(jí):OR=2.23(1.60~3.10),P0.01;3~4級(jí):OR=2.90(1.40~6.02),P0.01]、血小板減少[1~4級(jí):OR=2.40(1.56~3.69),P0.01]、貧血[3~4級(jí):OR=1.78(1.11~2.87),P=0.02]及腹瀉[3~4級(jí):OR=2.51(1.13~5.58),P=0.02]的發(fā)生率均高于5-FU組,而其他的消化系統(tǒng)不良事件發(fā)生率相對(duì)低于5-FU組,但僅1~4級(jí)惡心的發(fā)生率顯著低于5-FU組[OR=0.59(0.42~0.81),P0.01]。結(jié)論對(duì)于中國晚期胃癌患者,S-1可以顯著提高客觀緩解率及疾病控制率,但增加血液系統(tǒng)不良事件及腹瀉的發(fā)生率;而在生存時(shí)間方面雖不劣于5-FU。
[Abstract]:Objective to compare the efficacy and safety of Tegeo (S-1) and fluorouracil (5-FU) in patients with advanced gastric cancer in China. Methods to search China Zhiwang, Wanfang data and PubMed, search for Meta analysis of S-1 and 5-FU multicenter randomized controlled trial (mcRCTs),) using RevMan 5.2 software in patients with advanced gastric cancer in China. 緇撴灉綰沖叆4涓猰cRCTs.Meta鍒嗘瀽鏄劇ずS-1鍙互鏄捐憲鎻愰珮瀹㈣緙撹В鐜嘯OR=1.90,95%CI(1.36~2.65),P0.01]鍜岀柧鐥呮帶鍒剁巼[OR=2.08(1.43~3.03),P0.01],浣嗘湭鏄劇ず鍑烘，

本文編號(hào)：2278193